Liver

down-arrow-med

MASH Precis™ is Now Available

FibroSpect® NASH was developed to help differentiate patients with advanced fibrosis and cirrhosis (F3-F4) from those with F0-F2 fibrosis. As the MASH landscape continues to evolve, including the availability of therapies for patients with moderate-to-advanced fibrosis (F2-F3), clinicians increasingly need methods to identify patients earlier.

To support this need for identification, Prometheus Laboratories has introduced MASH Precis™ for adult patients (≥18 years of age). MASH Precis combines objective fibrosis staging, prognostic risk assessment and biomarker insights in a single test, providing actionable information to support patient management.

Performed exclusively at Prometheus Laboratories, MASH Precis helps address the growing need for accessible, scalable fibrosis assessment across healthcare settings. FibroSpect NASH remains available for clinicians who utilize it in patient care.

FibroSpect NASH Logo

Detect, stage and monitor liver fibrosis

What Is Nonalcoholic Steatohepatitis (NASH), now known as MASH?

  • Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive, inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD)
  • Often asymptomatic, MASH affects up to 20 million Americans, and prevalence is increasing alongside obesity and type 2 diabetes1
  • If left untreated, MASH is a leading cause of advanced liver fibrosis and cirrhosis and can progress to the need for liver transplant or hepatocellular cancer1

Identifying and treating patients early is imperative

  • Newly approved therapeutics can arrest or reverse liver fibrosis in patients with MASH
  • Advanced (F3–F4) fibrosis is the strongest independent predictor of mortality in patients with MASH2,3
  • Early assessment of fibrosis supports treatment selection and longitudinal disease management

Develop a patient care plan based on severity of liver fibrosis

  • Disease-specific algorithm differentiates F0-F2 and F3-F4 liver fibrosis
  • Fasting not required
  • Not impacted by patient age
Simple, noninvasive blood test that aids in the detection, staging and monitoring of liver fibrosis
FibroSpect NASH Test Report Explanation
References

1. Younossl ZM et al. Clin Mol Hepatol. 2025 Feb;31(Suppl):S32-S50.
2. Angulo P et al. Gastroenterology. 2015 Aug;149(2):389-97.e10.
3. Ekstedt M et al. Hepatology. 2015 May;61(5):1547-54.
4. Jayakumar S et al. Curr Hepatol Rep. 2016 Jun;15(2):86-95.
5. Loomba R et al. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1867-1876.e3.
6. Data on file.

FibroSpect NASH was developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendment (CLIA) laboratory guidelines, and is performed exclusively in our high complexity CLIA certified and College of American Pathologists (CAP) accredited clinical laboratory. As a laboratory developed test, it has not been cleared or approved by the US FDA. FibroSpect NASH and MASH Precis tests may be covered by one or more US pending or issued patents – see prometheuslabs.com for details. Prometheus, FibroSpect and MASH Precis are trademarks or registered trademarks of Prometheus Laboratories Inc, San Diego, California. All other trademarks and service marks are the property of their respective owners. This material is provided for general information purposes only, as an educational service for healthcare providers. It is not intended as a substitute for medical advice and/or consultation with a physician.